These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 17345593

  • 1. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
    Zhigang Z, Jieming L, Su L, Wenlu S.
    J Surg Oncol; 2007 Jul 01; 96(1):54-61. PubMed ID: 17345593
    [Abstract] [Full Text] [Related]

  • 2. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE, Holly J, Peters TJ, Donovan J, Persad R, Gillatt D, Pearce A, Hamdy FC, Neal DE, Gunnell D.
    Urology; 2004 Aug 01; 64(2):317-22. PubMed ID: 15302487
    [Abstract] [Full Text] [Related]

  • 3. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
    Jung K, Hoesel W, Reiche J, Deger S, Kramer J, Loening SA, Lein M, Stephan C.
    Urology; 2007 Feb 01; 69(2):320-5. PubMed ID: 17320672
    [Abstract] [Full Text] [Related]

  • 4. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y, Sakai H, Hayashi T, Kanetake H.
    Prostate; 2003 Feb 01; 54(2):125-32. PubMed ID: 12497585
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
    Partin AW, Brawer MK, Bartsch G, Horninger W, Taneja SS, Lepor H, Babaian R, Childs SJ, Stamey T, Fritsche HA, Sokoll L, Chan DW, Thiel RP, Cheli CD.
    J Urol; 2003 Nov 01; 170(5):1787-91. PubMed ID: 14532777
    [Abstract] [Full Text] [Related]

  • 9. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L, Bode C, Weiss C, Mayer D, Grobholz R, Alken P, Michel MS.
    Eur Urol; 2006 Feb 01; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
    Khosravi J, Diamandi A, Mistry J, Scorilas A.
    J Clin Endocrinol Metab; 2001 Feb 01; 86(2):694-9. PubMed ID: 11158033
    [Abstract] [Full Text] [Related]

  • 13. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
    Lein M, Jung K, Elgeti U, Brux B, Sinha P, Schnorr D, Loening SA.
    Anticancer Res; 2000 Feb 01; 20(6D):4997-5001. PubMed ID: 11326657
    [Abstract] [Full Text] [Related]

  • 14. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
    Stephan C, Cammann H, Deger S, Schrader M, Meyer HA, Miller K, Lein M, Jung K.
    Urology; 2009 Oct 01; 74(4):873-7. PubMed ID: 19476981
    [Abstract] [Full Text] [Related]

  • 15. Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
    Haese A, Vaisanen V, Lilja H, Kattan MW, Rittenhouse HG, Pettersson K, Chan DW, Huland H, Sokoll LJ, Partin AW.
    J Urol; 2005 Mar 01; 173(3):752-6. PubMed ID: 15711262
    [Abstract] [Full Text] [Related]

  • 16. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X, Truan D, Alcover J, Quintó L, Molina R, Luque P, Coca F, Ballesta AM.
    Urology; 2004 Jun 01; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, Veltri RW.
    J Urol; 2003 Sep 01; 170(3):723-6. PubMed ID: 12913682
    [Abstract] [Full Text] [Related]

  • 18. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M, Jung K, Hammerer P, Graefen M, Semjonow A, Stieber P, Ossendorf M, Luboldt HJ, Brux B, Stephan C, Schnorr D, Loening SA.
    Prostate; 2001 May 01; 47(2):77-84. PubMed ID: 11340629
    [Abstract] [Full Text] [Related]

  • 19. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
    Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D.
    Cancer Res; 2003 Jul 15; 63(14):3991-4. PubMed ID: 12873996
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.